A Phase 3 Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)

AstraZeneca1 个研究点目标入组 74 人开始时间: 待定最近更新: 2020年6月16日

试验速览

暂无简介。

•Documented evidence of Stage IV NSCLC
•No sensitizing EGFR mutation or ALK rearrangement
•No prior chemotherapy or any other systemic therapy for recurrent/metastatic NSCLC
•World Health Organization (WHO) Performance Status of 0 or 1

•Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant
•Brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)
•Prior exposure to Immunomodulatory therapy (IMT), including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies, excluding therapeutic anticancer vaccines
•Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease]

efficacy confirmatory pharmacogenomics -

未报告次要终点

发起方

Loading locations...